Popper and Company Announces Appointment of Senior Advisors
Aug 11 14
Popper and Company announced that it has added three industry veterans as senior advisors. Michael C. Little, Ph.D., who recently retired from his role as VP/Global Head Diagnostics Development, Companion Diagnostics Unit, Novartis Oncology; David L. Scher, M.D., pioneer adopter of remote patient monitoring and thought leader on the topic of digital health technology; and Niall Sweeney, an innovator of drug delivery, medical information, orthopedics and dentistry products, have joined the Popper and Company team. Each of these professionals brings deep operational business experience and further strengthens the capabilities that Popper and Company offers its clients as they address some of the most complex challenges facing the healthcare industry. Michael Little, Ph.D., joins Popper and Company following a long tenure in senior executive roles in the in vitro diagnostic (IVD) and companion diagnostic (CDx) industries, most recently at Novartis. David Lee Scher, M.D., is a cardiac electrophysiologist, and a pioneer adopter of remote patient monitoring and integration of monitored devices with electronic health records. Niall Sweeney has repeatedly grown businesses by delivering innovative medical products in markets such as drug delivery, medical information, orthopedics and dentistry.